Second-line and third-line therapy with nanoliposomal irinotecan (nal-IRI) in pancreatic cancer: a single-center experience and review of literature.
Journal of gastrointestinal oncology
View this publicationJournal of gastrointestinal oncology
View this publicationPloS one
View this publicationTherapeutic advances in musculoskeletal disease
View this publicationJournal of cancer research and clinical oncology
View this publicationRheumatology (Oxford, England)
View this publicationFrontiers in immunology
View this publicationCancer medicine
View this publicationBritish journal of haematology
View this publicationOncotarget
View this publicationJournal of cancer research and clinical oncology
View this publication